Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIDE study of siplizumab in new-onset type 1 diabetes
2023-506837-31-00Phase 2Completed
- Sponsor
- ITB-MED
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, single-blind trial in diabetes mellitus type 1 (T1D) comparing siplizumab with placebo (2 arms). Primary endpoint: Change from baseline in mean 4-hour stimulated C-peptide AUC following MMTT at Week 52 versus placebo. Started Sep 2023; status: completed.
02
Drugs
siplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2023-506837-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506837-31-00.